Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning founder and CIO, said that he agrees with the call and thinks the company’s ...

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products for Human Use (CHMP) has ...

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:LLY), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Carrie Agne (white dress) hugs trainer Cherie DeVaux after the 2-year-old colt named for Agne's late husband, Dr. Agne, won his career debut in the sixth race at Saratoga Race Course on Friday ...

Landon Perry went 2-for-2 with three RBIs to power Lilly Chiropractor to a 13-1 win over Brent Cogan Electric in a Greater City League/AAABA game at Vets Field on Thursday. Chad McCoy and Britton ...

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per share in Q1 2025, missing analysts’ consensus estimate of $4.64. Despite this, ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...